Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.